Tolerance Bio is developing a pipeline of therapies that target thymus biology to preserve, restore and modulate thymic function with the goal of re-establishing immune tolerance. Its pipeline modalities include monoclonal antibodies, cell therapies, and mRNA approaches. The company is advancing a celiac disease program that aims to retrain immune responses by targeting the thymus and is pursuing preclinical proof-of-concept work. Tolerance Bio positions its platform as potentially applicable beyond celiac disease to a broader set of autoimmune conditions. The company announced a strategic investment from Beyond Celiac Investments to support early development and accelerate its path to the clinic. No revenue, user, or other operating metrics were disclosed in the articles.

Total raised

$17M

Funding rounds

2

Latest round

Seed

Latest activity

Oct 2024